Centogene announced that it has received a notification from the Nasdaq Stock Market Listing Qualifications Department informing the Company that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1). As a result, CENTOGENE is now compliant with all applicable Nasdaq listing standards, and Nasdaq considers this matter closed. CENTOGENE was previously notified by Nasdaq on December 12, 2022, that it was not in compliance with the minimum bid price rule, because its common stock failed to meet the closing bid price of US$1.00 or more for 30 consecutive business days. To regain compliance with the minimum bid price rule, the Company was required to maintain a minimum closing bid price of US$1.00 for at least 10 consecutive business days. This requirement was met on February 3, 2023.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CNTG:
- CENTOGENE to Participate in Upcoming Conferences in February in the Lead Up to Rare Disease Day
- Twist Centogene launch target enrichment panels for rare disease diagnosis
- Centogene, Denali extend observational study on Parkinson’s disease genetics
- Centogene, Premier Research announce strategic partnership
- CENTOGENE Announces Its Attendance at the 41st Annual J.P. Morgan Healthcare Meeting and Fierce JPM Week in San Francisco
